$13.84
0.87% yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US08205P1003
Symbol
BNTC

Benitec Biopharma Inc Stock price

$13.84
-0.07 0.50% 1M
+0.83 6.38% 6M
+1.21 9.58% YTD
+4.03 41.08% 1Y
+8.48 158.37% 3Y
-40.56 74.56% 5Y
-1,127.72 98.79% 10Y
-196.16 93.41% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.12 0.87%
ISIN
US08205P1003
Symbol
BNTC
Industry

Key metrics

Basic
Market capitalization
$363.3m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-41.4m | $-36.2m
EBIT
$-41.8m | $-51.8m
Net Income
$-37.9m | -
Free Cash Flow
$-23.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-86.8% | 12.4%
EBIT
-85.7% | -24.1%
Net Income
-69.5% | -
Free Cash Flow
-20.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
$-0.9
FCF per Share
-
Short interest
9.1%
Employees
16
Rev per Employee
$0.0
Show more

Is Benitec Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Benitec Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Benitec Biopharma Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Benitec Biopharma Inc forecast:

Buy
93%
Hold
7%

Financial data from Benitec Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
286% 286%
-
- Research and Development Expense 27 27
72% 72%
-
-41 -41
87% 87%
-
- Depreciation and Amortization 0.40 0.40
18% 18%
-
EBIT (Operating Income) EBIT -42 -42
86% 86%
-
Net Profit -38 -38
70% 70%
-

In millions USD.

Don't miss a Thing! We will send you all news about Benitec Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Benitec Biopharma Inc Stock News

Neutral
GlobeNewsWire
12 days ago
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company de...
Positive
Seeking Alpha
6 months ago
We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing function, with significant commercial opportunities and an undervalued stock price reflecting high-dose cohort data. Financially, Benitec has no revenue, rising operating expenses, and a cash balance of ...
Negative
24/7 Wall Street
6 months ago
After struggling through a rough patch, the biotech industry seems to be staging a comeback.

Company Profile

Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.

Head office United States
CEO Jerel Banks
Employees 16
Founded 2019
Website benitec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today